Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pascal Benkert

Showing results (81-90 of 135) with videos related to

Pageof 14
Sort By:
Annals of Neurology|October 11, 2024
Advanced MRI Measures of Myelin and Axon Volume Identify Repair in Multiple SclerosisGretel Sanabria-Diaz, Alessandro Cagol, Po-Jui Lu, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|April 11, 2020
Monitoring of radiologic disease activity by serum neurofilaments in MSTomas Uher, Sabine Schaedelin, Barbora Srpova, et al.
Journal of Neuroinflammation|May 2, 2021
Serum GFAP and NfL as disease severity and prognostic biomarkers in patients with aquaporin-4 antibody-positive neuromyelitis optica spectrum disorderPatrick Schindler, Ulrike Grittner, Johanna Oechtering, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|April 19, 2023
Granulocyte activation markers in cerebrospinal fluid differentiate acute neuromyelitis spectrum disorder from multiple sclerosisDavid Leppert, Mitsuru Watanabe, Sabine Schaedelin, et al.
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)|January 13, 2026
Assessing the Relative Importance of Imaging and Serum Biomarkers in Capturing Disability, Cognitive Impairment, and Clinical Progression in Multiple SclerosisAlessandro Cagol, Pascal Benkert, Sabine Schaedelin, et al.
Molecular Neurobiology|March 14, 2026
NfL and GFAP quantification and associations with mental health in recreational cannabis users-Results from the Swiss study on recreational cannabis access via pharmaciesMaximilian Meyer, C Felix Mosandl, Adrian Guessoum, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|May 13, 2026
Serum Glial Fibrillary Acidic Protein and Retinal Neuronal Loss as Additive Prognostic Markers of Disability in Multiple SclerosisShaumiya Sellathurai, Kean Schoenholzer, Federico Burguet Villena, et al.
Multiple Sclerosis and Related Disorders|September 1, 2022
Serum glial fibrillary acidic protein correlates with retinal structural damage in aquaporin-4 antibody positive neuromyelitis optica spectrum disorderTing-Yi Lin, Patrick Schindler, Ulrike Grittner, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|June 5, 2025
Serum Neurofilament Light Chain as a Biomarker for CIDP Diagnosis, Severity, and Treatment OutcomeRafael Klimas, Felix Kohle, Lea Horstkemper, et al.
JAMA Neurology|August 13, 2019
Association Between Serum Neurofilament Light Chain Levels and Long-term Disease Course Among Patients With Multiple Sclerosis Followed up for 12 YearsEster Cantó, Christian Barro, Chao Zhao, et al.
Pageof 14

Showing results (81-90 of 135) with videos related to

Sort By:
Pageof 14
Annals of Neurology|October 11, 2024
Advanced MRI Measures of Myelin and Axon Volume Identify Repair in Multiple SclerosisGretel Sanabria-Diaz, Alessandro Cagol, Po-Jui Lu, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|April 11, 2020
Monitoring of radiologic disease activity by serum neurofilaments in MSTomas Uher, Sabine Schaedelin, Barbora Srpova, et al.
Journal of Neuroinflammation|May 2, 2021
Serum GFAP and NfL as disease severity and prognostic biomarkers in patients with aquaporin-4 antibody-positive neuromyelitis optica spectrum disorderPatrick Schindler, Ulrike Grittner, Johanna Oechtering, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|April 19, 2023
Granulocyte activation markers in cerebrospinal fluid differentiate acute neuromyelitis spectrum disorder from multiple sclerosisDavid Leppert, Mitsuru Watanabe, Sabine Schaedelin, et al.
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)|January 13, 2026
Assessing the Relative Importance of Imaging and Serum Biomarkers in Capturing Disability, Cognitive Impairment, and Clinical Progression in Multiple SclerosisAlessandro Cagol, Pascal Benkert, Sabine Schaedelin, et al.
Molecular Neurobiology|March 14, 2026
NfL and GFAP quantification and associations with mental health in recreational cannabis users-Results from the Swiss study on recreational cannabis access via pharmaciesMaximilian Meyer, C Felix Mosandl, Adrian Guessoum, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|May 13, 2026
Serum Glial Fibrillary Acidic Protein and Retinal Neuronal Loss as Additive Prognostic Markers of Disability in Multiple SclerosisShaumiya Sellathurai, Kean Schoenholzer, Federico Burguet Villena, et al.
Multiple Sclerosis and Related Disorders|September 1, 2022
Serum glial fibrillary acidic protein correlates with retinal structural damage in aquaporin-4 antibody positive neuromyelitis optica spectrum disorderTing-Yi Lin, Patrick Schindler, Ulrike Grittner, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|June 5, 2025
Serum Neurofilament Light Chain as a Biomarker for CIDP Diagnosis, Severity, and Treatment OutcomeRafael Klimas, Felix Kohle, Lea Horstkemper, et al.
JAMA Neurology|August 13, 2019
Association Between Serum Neurofilament Light Chain Levels and Long-term Disease Course Among Patients With Multiple Sclerosis Followed up for 12 YearsEster Cantó, Christian Barro, Chao Zhao, et al.
Pageof 14